AbbVie Jumps After Q4 Earnings Beat, Skyrizi And Rinvoq Boom Offsets Humira Decline
AbbVie Q4 earnings beat estimates, driven by strong sales of Skyrizi and Rinvoq, with an updated 2027 combined revenue forecast of $31 billion for both drugs.
ABBV Earnings: AbbVie Rallies Alongside Q4 Beats
AbbVie (ABBV) stock rallied today after the biopharmaceutical company posted its Q4 2024 earnings report. The good news begins with adjusted
AbbVie stock rises on solid annual profit guidance, Q4 beat
AbbVie (NYSE:ABBV) saw its shares jump more than 4% in premarket trading Friday after the company's profit guidance for the fiscal 2025 year exceeded analyst expectations, driven by strong sales in immunology drugs Skyrizi and Rinvoq.
AbbVie: Q4 Earnings Snapshot
AbbVie Inc. (ABBV) on Friday reported a fourth-quarter loss of $22 million, after reporting a profit in the same period a year earlier.
AbbVie: Q4 2024 Earnings Preview And Update On Emraclidine
In last year's update, AbbVie raised the combined 2027 net sales guidance for Skyrizi and Rinvoq by $6 billion to $27 billion. The company also raised the combined peak sales guidance of oral CGRP drugs Ubrelvy and Qulipta to more than $3 billion, and kept the rest unchanged.
AbbVie Vs. Novartis: Which Has The Technical Edge Before Q4 Earnings?
AbbVie and Novartis to report Q4 earnings. AbbVie in stagnating trend, Novartis bullish. Breakdown of technical charts. Novartis has advantage, investors watch for post-earnings movement.
AbbVie Stock Jumps on Earnings and Revenue Beat
The company anticipates earnings in a range of $12.12 to $12.32 a share. Analysts surveyed by FactSet expected $12.15 a share.
AbbVie swings to Q4 loss amid Cerevel impact; sets in-line guidance
AbbVie (NYSE:ABBV) traded higher in the premarket on Friday after setting its 2025 earnings outlook in line with expectations ...
AbbVie reports Q4 adjusted EPS $2.16, consensus $2.26
Reports Q4 revenue $15.1B, consensus $14.83B. “2024 was a year of significant progress for AbbVie (ABBV). Our growth platform delivered ...
AbbVie forecasts 2025 profit above estimates, driven by newer immunology drugs
AbbVie forecast 2025 profit above estimates on Friday, as strong sales of its newer immunology drugs Skyrizi and Rinvoq make up for a steep decline in those of Humira, its flagship rheumatoid ...
AbbVie Q4 2024 Earnings Preview: Strong results expected on Skyrizi, Rinvoq growth trajectory
AbbVie (ABBV) is expected to beat Q4 earnings estimates with strong performance from key products, including Skyrizi and ...
If You Invested $10,000 In AbbVie Stock 10 Years Ago, How Much Would You Have Now?
AbbVie Inc. (NYSE:ABBV) discovers, develops, manufactures and sells pharmaceuticals worldwide. It is set to report the Q4 ...
Why ABBV Is Rallying Today
AbbVie (ABBV), a large drug maker, is jumping 8% after the company provided significantly higher-than-expected 2025 earnings ...